^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Peripheral T-cell Lymphoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Peripheral T-cell Lymphoma: Second-line therapy (with initention to proceed to transplant) and subsequent therapy...Other recommended regimens…Crizotinib (ALK+ ALCL only)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non-Hodgkin’s Lymphoma)
    New
    Excerpt:
    XALKORI is a kinase inhibitor indicated for the treatment of…pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.